VRTX Aperçu des actions Vertex Pharmaceuticals Incorporated, société de biotechnologie, développe et commercialise des thérapies pour le traitement de la fibrose kystique (FK). Plus de détails
Récompenses Analyse des risques Voir tous les contrôles de risques Saisissez vos pensées, vos liens et l'histoire de votre entreprise
Vertex Pharmaceuticals Incorporated Concurrents Historique des prix et performances
Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 Vertex Pharmaceuticals Historique des cours de bourse Prix actuel de l'action US$447.90 Plus haut sur 52 semaines US$487.50 Plus bas sur 52 semaines US$360.45 Bêta 0.40 Variation sur 1 mois 14.33% Variation sur 3 mois 3.26% Variation sur 1 an 13.06% Variation sur 3 ans 112.12% Variation sur 5 ans 106.07% Évolution depuis l'introduction en bourse 325.46%
Nouvelles et mises à jour récentes
Vertex Pharmaceuticals Incorporated Announces FDA Approval of Journavx (Suzetrigine), A First-In-Class Treatment for Adults with Moderate-To-Severe Acute Pain Jan 31
Vertex Pharmaceuticals Incorporated to Report Q4, 2024 Results on Feb 10, 2025 Jan 27
Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval for Trialta® (elexacaftor/ivacaftor andivacaftor) to Include Additional Non-F508del TrialKAFTA-Responsive Variants Dec 21
New minor risk - Share price stability Dec 19
Vertex Pharmaceuticals Incorporated Announces Results from Phase 2 Study of Suzetrigine for Treatment of Painful Lumbosacral Radiculopathy Dec 19
Vertex Pharmaceuticals Incorporated Presents Positive Long-Term Data on Casgevy at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update Dec 09 Voir plus de mises à jour
Vertex Pharmaceuticals Incorporated Announces FDA Approval of Journavx (Suzetrigine), A First-In-Class Treatment for Adults with Moderate-To-Severe Acute Pain Jan 31
Vertex Pharmaceuticals Incorporated to Report Q4, 2024 Results on Feb 10, 2025 Jan 27
Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval for Trialta® (elexacaftor/ivacaftor andivacaftor) to Include Additional Non-F508del TrialKAFTA-Responsive Variants Dec 21
New minor risk - Share price stability Dec 19
Vertex Pharmaceuticals Incorporated Announces Results from Phase 2 Study of Suzetrigine for Treatment of Painful Lumbosacral Radiculopathy Dec 19
Vertex Pharmaceuticals Incorporated Presents Positive Long-Term Data on Casgevy at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update Dec 09
Third quarter 2024 earnings released: EPS: US$4.05 (vs US$4.01 in 3Q 2023) Nov 05
Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024 Nov 05
Vertex Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 04, 2024 Oct 11
Second quarter 2024 earnings released: US$13.92 loss per share (vs US$3.55 profit in 2Q 2023) Aug 02
Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024 Aug 02
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-To-Severe Acute Pain Jul 31 Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for Trikafa® for People with Cystic Fibrosis Aged 2 Years and Older with Certain Rare Mutations Jul 16
Vertex Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 01, 2024
Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Jun 22
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders. May 21
Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director May 16
Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024 May 08
First quarter 2024 earnings released: EPS: US$4.26 (vs US$2.72 in 1Q 2023) May 07
Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older Apr 27
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion. Apr 11
Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024 Apr 10
Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024 Apr 05 Vertex Pharmaceuticals Incorporated Announces New Drug Submission for Exagamglogene Autotemcel (Exa-Cel) Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older Feb 23
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Feb 13
Vertex Pharmaceuticals Incorporated Announces Positive Results from Pivotal Trials of Vanza Triple Combination Treatment for Cystic Fibrosis Feb 07
Full year 2023 earnings released: EPS: US$14.05 (vs US$12.97 in FY 2022) Feb 06
Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024 Feb 06
Vertex Announces Positive Results from the VX-548 Phase 3 Program for the Treatment of Moderate-To-Severe Acute Pain Jan 30
Vertex Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 05, 2024 Jan 18
Vertex Pharmaceuticals Incorporated Announces US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia Jan 17
Vertex Pharmaceuticals Incorporated Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi Jan 10
Vertex Pharmaceuticals Incorporated Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Dec 16
Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy Dec 14 CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States
Vertex Pharmaceuticals Incorporated Appoints Nancy Thornberry to Its Board of Directors as an Independent Director Dec 06
Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older Nov 30
Vertex Pharmaceuticals Incorporated Announces European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5 Nov 24
Vertex Pharmaceuticals Incorporated Announces United Kingdom Medicines and Healthcare Products Regulatory Agency Granted Conditional Marketing Authorization for CASGEVY Nov 17
Third quarter 2023 earnings released: EPS: US$4.01 (vs US$3.63 in 3Q 2022) Nov 08
Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Market Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With at Least One F508del Mutation Oct 18
Vertex Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 06, 2023 Oct 11
Vertex Pharmaceuticals Incorporated Appoints Michel Lagarde to Its Board of Directors Oct 06
Vertex Pharmaceuticals Incorporated Receives Chmp Positive Opinion for Kaftrio® (Ivacaftor/Tezacaftor/Elexacaftor) in Combination with Ivacaftor for Children with Cystic Fibrosis Ages 2 Through 5 Sep 16
Vertex Pharmaceuticals Incorporated Appoints E. Morrey Atkinson, Ph.D., as Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations Aug 30
Vertex Pharmaceuticals Incorporated Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine Aug 04
Second quarter 2023 earnings released: EPS: US$3.55 (vs US$3.17 in 2Q 2022) Aug 02
Vertex Pharmaceuticals Incorporated Announces European Commission Approval for ORKAMBI® (Lumacaftor/Ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 1 to <2 Years Old Jul 06
Insufficient new directors Jul 01
Vertex Pharmaceuticals Incorporated Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions Jun 24
Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Jun 10 Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Jun 09
First quarter 2023 earnings released: EPS: US$2.72 (vs US$2.99 in 1Q 2022) May 03
Full year 2022 earnings released: EPS: US$12.97 (vs US$9.09 in FY 2021) Feb 08
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces an Equity Buyback for $3,000 million worth of its shares. Feb 08
Vertex Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 07, 2023 Jan 18
Vertex Pharmaceuticals Incorporated Announces to Present New Data on its Portfolio of Cystic Fibrosis Medicines at 2022 North American Cystic Fibrosis Conference Nov 04
Third quarter 2022 earnings released: EPS: US$3.63 (vs US$3.30 in 3Q 2021) Oct 28
Vertex Pharmaceuticals Incorporated Revises Revenue Guidance for the Fiscal 2022 Oct 28
Vertex Pharmaceuticals Incorporated to Report Q3, 2022 Results on Oct 27, 2022 Oct 14
Vertex Pharmaceuticals Incorporated Advances Program Targeting Alpha-1 Antitrypsin Deficiency Oct 12
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022 Sep 28
Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022 Sep 10
Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022 Sep 09
Vertex Announces U.S. FDA Approval for Orkambi® (Lumacaftor/Ivacaftor) in Children with Cystic Fibrosis Ages 12 to <24 Months Sep 03
Second quarter 2022 earnings released: EPS: US$3.17 (vs US$0.26 in 2Q 2021) Aug 05
Vertex Pharmaceuticals Incorporated Reports Unaudited Intangible Asset Impairment Charge for the Three Months Ended June 30, 2022 Aug 05
Vertex Advances VX-548 in Acute and Neuropathic Pain Jul 23
Vertex Pharmaceuticals Incorporated to Report Q2, 2022 Results on Aug 04, 2022 Jul 19
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million. Jul 13
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million. Jul 12
Vertex Announces FDA Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes Jul 06
Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference Jun 11
Vertex Pharmaceuticals Incorporated Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA Jun 09
Vertex Pharmaceuticals Incorporated to Present New Data on VX-880 Clinical Trial Jun 01
Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million. May 25
Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million. May 24
Vertex Pharmaceuticals Incorporated Elects Suketu Upadhyay as Independent Director May 19
First quarter 2022 earnings released: EPS: US$2.99 (vs US$2.52 in 1Q 2021) May 06
Vertex Pharmaceuticals Incorporated Reiterates Earning Guidance for 2022 May 06
Vertex Pharmaceuticals Incorporated to Report Q1, 2022 Results on May 05, 2022 Apr 22
Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for TRIKAFTA in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation Apr 21
Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 18, 2022 Apr 08
Vertex Pharmaceuticals Incorporated Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain Apr 01
Vertex Pharmaceuticals Incorporated Announces Reimbursement Agreement in Australia for TRIKAFTA Mar 28
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Jan 28
Vertex Pharmaceuticals Incorporated Provides Full Year 2022 Financial Guidance Jan 27
Vertex Pharmaceuticals Incorporated announces European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) Jan 12
Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis Dec 02
Third quarter 2021 earnings released: EPS US$3.30 (vs US$2.56 in 3Q 2020) Nov 03
Vertex Pharmaceuticals Incorporated Announces Its Supplement to a New Drug Submission for PrKALYDECO Sep 24
Vertex Pharmaceuticals Incorporated Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis Aug 27
CEO, President & Director recently bought €1.7m worth of stock Aug 25 Rendement pour les actionnaires VRTX AT Biotechs AT Marché 7D 7.0% 0.6% 0.9% 1Y 13.1% 20.1% 5.9%
Voir le rapport complet des actionnaires
Rendement vs Industrie: VRTX a sous-performé le secteur Austrian Biotechs qui a rapporté 20.1 % au cours de l'année écoulée.
Rendement vs marché: VRTX a dépassé le marché Austrian qui a rapporté 5.9 % au cours de l'année écoulée.
Volatilité des prix Is VRTX's price volatile compared to industry and market? VRTX volatility VRTX Average Weekly Movement 6.0% Biotechs Industry Average Movement 7.8% Market Average Movement 3.9% 10% most volatile stocks in AT Market 6.1% 10% least volatile stocks in AT Market 2.0%
Cours de l'action stable: Le cours de l'action de VRTX a été volatil au cours des 3 derniers mois par rapport au marché Austrian.
Volatilité au fil du temps: La volatilité hebdomadaire de VRTX ( 6% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de Austrian.
À propos de l'entreprise Fondée Salariés PDG Site web 1989 5,400 Reshma Kewalramani www.vrtx.com
Vertex Pharmaceuticals Incorporated, société de biotechnologie, développe et commercialise des thérapies pour le traitement de la fibrose kystique (FK). Elle commercialise TRIKAFTA/KAFTRIO pour les personnes atteintes de FK présentant au moins une mutation F508del et âgées de 2 ans ou plus ; SYMDEKO/SYMKEVI pour les personnes atteintes de FK et âgées de 6 ans ou plus ; ORKAMBI pour les patients atteints de FK âgés de 1 an ou plus ; et KALYDECO pour le traitement des patients atteints de FK âgés de 1 an ou plus à l'aide de l'ivacaftor. Le portefeuille de produits de l'entreprise comprend VX-522, un médicament à base d'ARNm CFTR conçu pour traiter la cause sous-jacente de la FK, qui est en essai clinique de phase 1 ; VX-548, un médicament non opioïde pour le traitement de la douleur aiguë et neuropathique, qui est en essai clinique de phase 3 ; Exa-cel, pour le traitement de la drépanocytose et de la bêta-thalassémie dépendante des transfusions, qui est en essai clinique de phase 2/3.
Afficher plus Vertex Pharmaceuticals Incorporated Résumé des fondamentaux Comment les bénéfices et les revenus de Vertex Pharmaceuticals se comparent-ils à sa capitalisation boursière ? VRTX statistiques fondamentales Capitalisation boursière €108.57b Bénéfices(TTM) -€461.38m Recettes(TTM ) €10.22b
Bénéfices et recettes Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM) VRTX compte de résultat (TTM ) Recettes US$10.63b Coût des recettes US$4.93b Marge brute US$5.69b Autres dépenses US$6.17b Les revenus -US$479.80m
Derniers bénéfices déclarés
Sep 30, 2024
Prochaine date de publication des résultats
Feb 10, 2025
Résultat par action (EPS) -1.86 Marge brute 53.59% Marge bénéficiaire nette -4.52% Ratio dettes/capitaux propres 0%
Quelles ont été les performances à long terme de VRTX?
Voir les performances historiques et les comparaisons
Analyse de l'entreprise et données financières Données Dernière mise à jour (heure UTC) Analyse de l'entreprise 2025/01/31 17:00 Cours de l'action en fin de journée 2025/01/31 00:00 Les revenus 2024/09/30 Revenus annuels 2023/12/31
Sources de données Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC . Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
Paquet Données Cadre temporel Exemple de source américaine * Finances de l'entreprise 10 ans Compte de résultat Tableau des flux de trésorerie Bilan Estimations consensuelles des analystes +3 ans Prévisions financières Objectifs de prix des analystes Prix du marché 30 ans Cours des actions Dividendes, scissions et actions Propriété 10 ans Actionnaires principaux Délits d'initiés Gestion 10 ans L'équipe dirigeante Conseil d'administration Principaux développements 10 ans
* exemple pour les titres américains, pour les titres non-américains des formulaires et sources réglementaires équivalents sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). Pour en savoir plus , cliquez ici .
Modèle d'analyse et flocon de neige Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github . Nous avons également des guides sur la façon d'utiliser nos rapports et des tutoriels sur Youtube .
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur .
Sources des analystes Vertex Pharmaceuticals Incorporated est couverte par 75 analystes. 31 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
Analyste Institution Jasper Hellweg Argus Research Company Brian Skorney Baird Ishan Majumdar Baptista Research
Afficher 72 plus d'analystes 
